Clinical trials: Glioma, Malignant
Neoplasms
A Study of BXQ-350 in Children and Young Adults With Relapsed Solid Tumors
This study will evaluate the safety of BXQ-350 and determine the maximum tolerated dose (MTD) in children and young adults with relapsed solid tumors, including recurrent malignant brain tumors.
- Trial name
- KOURAGE (NCT03967093)
- Testing
- BXQ-350
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Bexion Pharmaceuticals, Inc.
Malignant Glioma
Bevacizumab Plus Irinotecan Plus Carboplatin for Recurrent Malignant Glioma (MG)
The purpose of this study is to determine whether Bevacizumab, CPT-11 and Carboplatin in combination are effective in the treatment of recurrent malignant glioma.
- Trial name
- NCT00953121
- Testing
- bevacizumab and CPT-11 and Carboplatin
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- Annick Desjardins
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
This phase II Pediatric MATCH trial studies how well olaparib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with defects in deoxyribonucleic acid (DNA) damage repair genes that have…
- Conditions
- Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma, Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma, Low Grade Glioma
- Trial name
- NCT03233204
- Testing
- Olaparib
- Where
- 113 sites in United States, Puerto Rico
- Volunteers
- 6 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Giving chemotherapy with peripheral stem cell or bone marrow transplant may allow the doctor to give…
- Trial name
- NCT00008008
- Testing
- filgrastim, sargramostim, cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Herbert Irving Comprehensive Cancer Center
Brain and Central Nervous System Tumors
Radiation Therapy in Treating Patients With Progressive or Recurrent Malignant Brain Tumors
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Giving radiation therapy in different ways may kill more tumor cells.
- Trial name
- NCT00003574
- Testing
- surgical procedure, brachytherapy, intraoperative radiation therapy
- Where
- 9 sites in United States
- Sponsor
- New Approaches to Brain Tumor Therapy Consortium
Solid Tumour, Haematological Malignancy
DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations
This clinical trial is looking at a drug called capmatinib. Capmatinib is approved as standard of care treatment for adult patients with certain types of lung cancer.
- Conditions
- Solid Tumour, Haematological Malignancy, Malignant Neoplasm, Neoplasms by Histologic Type
- Trial name
- DETERMINE (NCT06988475)
- Testing
- Capmatinib
- Where
- 17 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
High-grade Glioma, Astrocytoma
Assessment of 18FLT PET-CT for Volume Definition of High-grade Gliomas (GLIO-TEP)
18F-Fluorothymidine is a recently developed PET tracer to image tumor cell proliferation. Very few data report an interest of using such a tracer for cerebral malignant tumor management.
- Conditions
- High-grade Glioma, Astrocytoma, Glioblastoma
- Trial name
- GLIO-TEP (NCT00624728)
- Testing
- 18F Fluorothymidine PET CT
- Where
- 2 sites in France
- Volunteers
- 21 people
- Sponsor
- University Hospital, Bordeaux
Malignant Glioma
A Randomized Placebo-Controlled Trial of Armodafinil (Nuvigil) for Fatigue in Patients With Malignant Gliomas
The purpose of this research study is to determine if armodafinil is safe and effective in treating fatigue in patients with malignant gliomas undergoing treatment with radiotherapy plus temodar.
- Trial name
- NCT00766467
- Testing
- Armodafinil
- Where
- 4 sites in United States
- Volunteers
- 81 people
- Sponsor
- Eudocia Quant Lee, MD
Glioblastoma, Malignant Glioma
Cytomegalovirus (CMV) RNA-Pulsed Dendritic Cells for Pediatric Patients and Young Adults With WHO Grade IV Glioma, Recurrent Malignant Glioma, or Recurrent Medulloblastoma
The purpose of this study is to determine the feasibility and safety of administering CMV RNA-pulsed dendritic cells (DCs), also known as CMV-DCs, to children and young adults up to 35 years old with nWHO Grade IV glioma…
- Conditions
- Glioblastoma, Malignant Glioma, Medulloblastoma Recurrent, Pediatric Glioblastoma Multiforme
- Trial name
- ATTAC-P (NCT03615404)
- Testing
- CMV-DCs with GM-CSF, Td (tetanus toxoid)
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Gary Archer Ph.D.
Glioblastoma, Malignant Glioma
Dexamethasone and Azeliragon for Management of Post-Resection Cerebral Edema in Patients with Glioblastoma
This phase I trial tests the safety, side effects, and best dose of dexamethasone when given with azeliragon in managing cerebral edema after surgery (post-resection) in patients with glioblastoma.
- Trial name
- NCT05773664
- Testing
- Azeliragon, Biospecimen Collection, Computed Tomography
- Sponsor
- City of Hope Medical Center
Malignant Glioma (WHO Grade III or IV)
Ph 1/2 CTO With Lomustine for Bevacizumab-Naive Recurrent Glioma
This is a Phase 1/2 study of the combination of CTO with lomustine in patients with recurrent malignant glioma to be treated at the Preston Robert Tisch Brain Tumor Center (PRTBTC) at Duke.
- Trial name
- NCT01989052
- Testing
- CTO, Lomustine
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Annick Desjardins
High-grade Glioma
Integrating Biology for Safe Intensification of Glioblastoma Hypofractionated Treatment on the MR-Linac
This is a phase 1 study to examine the safety and tolerability of biology-guided dose intensified hypofractionated radiation therapy (RT) using MR-Linac for patients with high grade glioma (HGG).
- Trial name
- INSIGHT MRL (NCT07457307)
- Testing
- MR-Linac System, Radiation Therapy, Temozolomide
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- NYU Langone Health
Glioma, Astrocytoma
Temozolomide All-Case-Registered Surveillance (Designated Drug Use Investigation)(Study P05062)
The purpose of this study is to confirm the safety and efficacy of temozolomide in patients with newly diagnosed malignant glioma (concomitant with radiotherapy and then as monotherapy) and relapsed malignant glioma (as…
- Trial name
- NCT00705198
- Testing
- Temozolomide (for newly diagnosed malignant glioma), Temozolomide (for relapsed malignant glioma), Radiotherapy (for patients with newly diagnosed malignant glioma)
- Volunteers
- 1,804 people
- Sponsor
- Merck Sharp & Dohme LLC
Recurrent High-grade Glioma
Study to Assess Xevinapant in Preoperative Subjects With Recurrent High-Grade Glioma (rHGG)
Researchers will investigate the ability of Xevinapant to cross the blood-brain barrier and exert anti-tumor effects on rHGG through activation of apoptosis.
- Trial name
- NCT06463184
- Testing
- Xevinapant
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Recurrent Malignant Glioma
Clinical Trial of IV OKN-007 in a Pilot Cohort of Human Recurrent Malignant Glioma Patients
This is an open label Phase 1b clinical trial of IV administration of OKN-007 in a pilot cohort of human recurrent malignant glioma patients.
- Trial name
- OKN-007 (NCT01672463)
- Testing
- OKN-007
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Oblato, Inc.
Glioblastoma, Gliosarcoma
A Phase I Trial of Nanoliposomal CPT-11 (NL CPT-11) in Patients With Recurrent High-Grade Gliomas
This is a Phase I study of Nanoliposomal CPT-11 in patients with Recurrent high-grade gliomas. Patients must have a histologically proven intracranial malignant glioma, which includes glioblastoma multiforme (GBM), gliosarcoma…
- Conditions
- Glioblastoma, Gliosarcoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma
- Trial name
- NCT00734682
- Testing
- Nanoliposomal CPT-11
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of California, San Francisco
Brain and Central Nervous System Tumors
Radiation Therapy, Arsenic Trioxide, and Temozolomide in Treating Patients With Newly Diagnosed High-Grade Glioma
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as arsenic trioxide and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the…
- Trial name
- NCT00720564
- Testing
- arsenic trioxide, temozolomide, adjuvant therapy
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- City of Hope Medical Center
High Grade Glioma, Diffuse Intrinsic Pontine Glioma
PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
This study will address the question of whether targeting CMV antigens with PEP-CMV can serve as a novel immunotherapeutic approach in pediatric patients with newly-diagnosed high-grade glioma (HGG) or diffuse intrinsic pontine…
- Conditions
- High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Recurrent Medulloblastoma
- Trial name
- NCT05096481
- Testing
- PEP-CMV, Temozolomide, Tetanus Diphtheria Vaccine
- Where
- 13 sites in United States
- Volunteers
- 120 people
- Sponsor
- Nationwide Children's Hospital
Glioma, Diffuse Intrinsic Pontine Glioma
A Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas
This phase 2 trial will evaluate the activity of Panobinostat in combination with Everolimus for children with gliomas harboring H3.1 or H3.3K27M mutation, including newly diagnosed high-grade glioma or DIPG (diffuse intrinsic…
- Trial name
- NCT03632317
- Testing
- Panobinostat, Everolimus
- Where
- United States
- Sponsor
- University of Michigan Rogel Cancer Center
Malignant Glioma, Glioblastoma
CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII
Background: The National Cancer Institute (NCI) Surgery Branch has developed an experimental therapy for treating patients with gliomas that involves taking white blood cells from the patient, growing them in the laboratory in…
- Conditions
- Malignant Glioma, Glioblastoma, Brain Cancer, Gliosarcoma
- Trial name
- NCT01454596
- Testing
- Epidermal growth factor receptor(EGFRv)III Chimeric antigen receptor (CAR) transduced PBL, Aldesleukin, Fludarabine
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.